Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Epirubicin, Docetaxel Induction for Breast Cancer
NCT00193050Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Nov 2001
- Primary completion
- Mar 2008
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, epirubicin and docetaxel in breast cancer, sponsored by SCRI Development Innovations. Primary endpoint: Pathologic Complete Response at 18 months. Started Nov 2001; status: completed.
02
Drugs
gemcitabineepirubicindocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00193050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193050.